Insights from analysts' 12-month price targets are revealed, presenting an average target of $49.8, a high estimate of $52.00 ...
Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using ...
Eisai And Nuvation Bio Enter Into Exclusive Licensing Agreement For Taletrectinib In Europe And Additional Countries Outside The U.S., China And Japan. Eisai and Nuvation Bio Enter into Exclusive ...
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued stocks in the Biotechnology industry for Tuesday, January 13, 2026. Let’s ...
A new study led by researchers at National Jewish Health provides quantitative evidence linking burn pit smoke exposure during military deployment to increases in harmful carbon-based particles in the ...
A new report from the American Cancer Association predicts lung cancer will cause more deaths than any other in 2026.
A research team at the Medical University of Vienna has discovered a new approach to treating a particularly frequent and ...
A 45-year-old woman presents with long-standing exertional dyspnea, wheezing, and intermittent dry cough, which has been ongoing for over the past 10 years.
Pulmonary hypertension life expectancy and prognosis can vary broadly, but have improved in the era of modern treatment.
Merck Still Wants to "Grow Through Keytruda," Expects $70B in Revenue From New Programs by Mid-2030s
Two antibody-drug conjugates are among 10 programs that the company expects to fuel its growth, the company said.
Columnist Ann Reynoso may have looked well during a recent holiday gathering, but living with PF meant she was battling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback